[en] OBJECTIVE: To determine matrix metalloproteinase-3 (MMP-3) serum levels in
patients with rheumatic diseases and to study the relation between MMP-3 and C
reactive protein (CRP) levels. METHODS: MMP-3 serum levels were determined by
enzyme linked immunosorbent assay (ELISA) in (a) patients with active
inflammatory rheumatic diseases: rheumatoid arthritis (RA), psoriatic arthritis,
polymyalgia rheumatica, acute crystal arthritis, and ankylosing spondylitis; (b)
patients with active inflammatory systemic diseases: cutaneo-articular or renal
systemic lupus erythematosus (SLE), systemic sclerosis, and vasculitides; (c)
patients with non-inflammatory rheumatic diseases: osteoarthritis and
fibromyalgia; (d) critically ill patients without rheumatic diseases,
representing an acute inflammatory control group; (e) healthy controls. RESULTS:
MMP-3 serum levels were significantly increased in patients with active RA,
psoriatic arthritis, and polymyalgia rheumatica, whether treated or not by
corticosteroids, and in female patients with acute crystal arthritis. MMP-3 serum
levels were normal in steroid-free patients with active cutaneo-articular or
renal SLE, systemic sclerosis, and vasculitides but were significantly increased
in steroid treated patients. MMP-3 levels were normal in fibromyalgia,
osteoarthritis, ankylosing spondylitis, and acute inflammatory controls. MMP-3
was significantly correlated with CRP in RA (r=0.5, p=0.0004) but not in any of
the other disease groups. CONCLUSIONS: MMP-3 serum levels are increased in
inflammatory rheumatic diseases characterised by joint synovitis, such as RA,
polymyalgia rheumatica, psoriatic arthritis, and acute crystal arthritis-that is,
whether the diseases are acute or chronic, erosive or not. They are normal in
SLE, systemic sclerosis, and vasculitides as well as in non-rheumatic
inflammatory controls, but are significantly increased by steroids. These data
strongly suggest that serum MMP-3 reflects synovial inflammation.
Disciplines :
Rheumatology
Author, co-author :
Ribbens, Clio ; Université de Liège - ULiège > Rhumatologie
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Vincenti M.P., Clark I.M., Brinckerhoff C.E. (1994) Using inhibitors of metalloproteinases to treat arthritis. Easier said than done?. Arthritis Rheum 37:1115-1126.
Cawston T. (1998) Matrix metalloproteinases and TIMPs: Properties and implications for the rheumatic diseases. Mol Med Today 4:130-137.
Birkedal-Hansen H., Moore W.G.I., Bodden M.K., Windsor L.J., Birkedal-Hansen B., DeCarlo A. (1993) Matrix metalloproteinases: A review. Crit Rev Oral Biol Med 4:197-250.
Murphy G., Cockett M.I., Stephens P.E., Smith B.J., Docherty A.J.P. (1987) Stromelysin is an activator of procollagenase. Biochem J 248:265-268.
Ogata Y., Enghild J.J., Nagase H. (1992) Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem 267:3581-3584.
Sasaki S., Iwata H., Ishiguro N., Obata K., Miura T. (1994) Detection of stromelysin in synovial fluid and serum from patients with rheumatoid arthritis and osteoarthritis. Clin Rheumatol 13:228-233.
Taylor D.J., Cheung N.T., Dawes P.T. (1994) Increased serum proMMP-3 in inflammatory arthritides: A potential indicator of synovial inflammatory monokine activity. Ann Rheum Dis 53:768-772.
Yoshihara Y., Obata K., Fujimoto N., Yamashita K., Hayakawa T., Shimmei M. (1995) Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis. Arthritis Rheum 38:969-975.
Manicourt D.H., Fujimoto N., Obata K., Thonar E.J.M.A. (1995) Levels of circulating collagenase, stromelysin-1, and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis. Relationship to serum levels of antigenic keratan sulfate and systemic parameters of inflammation. Arthritis Rheum 38:1031-1039.
Ribbens C., Andre B., Jaspar J.M., Kaye O., Kaiser M.J., De Groote D. (2000) Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis. J Rheumatol 27:888-893.
Ishiguro N., Ito T., Obata K.I., Jujimoto N., Iwata H. (1996) Determination of stromelysin-1, 72 and 92 kDA type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis. J Rheumatol 23:1599-1604.
Cheung N.T., Taylor D.J., Evans E., Close D.R., Mattey D.L., Sahu P. (1996) Yttrium-90 synovectomy decreases circulating pro-metalloproteinase-3 in recurrent synovitis [abstract]. Rheumatology in Europe 25(SUPPL.).
Keyszer G., Lambiri I., Nagel R., Keysser C., Keysser M., Gromnica-Ihle E. (1999) Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. J Rheumatol 26:251-258.
Cheung N.T., Dawes P.T., Poulton K.V., Ollier W.E.R., Taylor D.J., Mattey D.L. (2000) High serum levels of pro-matrix metalloproteinase-3 are associated with greater radiographic damage and the presence of the shared epitope in patients with rheumatoid arthritis. J Rheumatol 27:882-887.
Yamanaka H., Matsuda Y., Tanaka M., Sendo W., Nakajima H., Taniguchi A. (2000) Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 43:852-858.
Kotajima L., Aotsuka S., Fujimani M., Okawa-Takatsuji M., Kinoshita M., Sumiya M. (1998) Increased levels of matrix metalloproteinase-3 in sera from patients with active lupus nephritis. Clin Exp Rheumatol 16:409-415.
Zucker S., Mian N., Drews M., Conner C., Davidson A., Miller F. (1999) Increased serum stromelysin-1 levels in systemic lupus erythematosus: Lack of correlation with disease activity. J Rheumatol 26:78-80.
Akiyama K., Shikata K., Sugimoto H., Matsuda M., Shikata Y., Fujimoto N. (1997) Changes in serum concentrations of matrix metalloproteinases, tissue inhibitors of metalloproteinases and type IV collagen in patients with various types of glomerulonephritis. Res Commun Mol Pathol Pharmacol 95:115-128.
Sharif M., Salisbury C., Taylor D.J., Kirwan J.R. (1998) Changes in biochemical markers of joint tissue metabolism in a randomized controlled trial of glucocorticoid in early rheumatoid arthritis. Arthritis Rheum 41:1203-1209.
Altman R.D. (1991) Criteria for classification of clinical osteoarthritis. J Rheumatol 18(SUPPL. 27):10-12.
Wolfe F., Smythe H.A., Yunus M.B., Bennett R.M., Bombardier C., Goldenberg D.L. (1990) The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum 33:160-172.
Ribbens C., Andre B., Kaye O., Kaiser M.J., Bonnet V., Jaspar J.M. (2000) Synovial fluid MMP-3 levels are increased in inflammatory arthritides whether erosive or not. Rheumatology (Oxford) 39:1357-1365.
Dougados M., Van der Linden S., Juhlin R., Huitfeldt B., Amor B., Calin A. (1991) The European Spondylarthropathy Study Group preliminary criteria for the classification of spondlylarthropathy. Arthritis Rheum 34:1218-1227.
Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumataid arthritis. Arthritis Rheum 31:315-324.
Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F. (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271-1277.
Masi A.T., Rodnan G.P., Medsger Jr. T.A. (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581-590.
Lightfoot Jr. R.W., Michel B.A., Bloch D.A., Hunder G.G., Zvaifler N.J., McShane D.J. (1990) The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 33:1088-1093.
Leavitt R.Y., Fauci A.S., Bloch D.A., Michel B.A., Hunder G.G., Arend W.P. (1990) The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 33:1101-1107.
Hunder G.G., Bloch D.A., Michel B.A., Stevens M.B., Arend W.P., Calabrese L.H. (1990) The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33:1122-1128.
Calabrese L.H., Michel B.A., Bloch D.A., Arend W.P., Edworthy S.M., Fauci A.S. (1990) The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis. Arthritis Rheum 33:1108-1113.
Brennan F.M., Browne K.A., Green P.A., Jaspar J.M., Maini R.N., Feldmann M. (1997) Reduction of serum matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumor necrosis factor-α (cA2) therapy. Br J Rheumatol 36:643-650.
Partsch G., Wagner E., Leeb B.F., Dunky A., Steiner G., Smolen J.S. (1998) Upregulation of cytokine receptors sTNF-R55, sTNF-R75, and slL-2R in psoriatic arthritis synovial fluid. J Rheumatol 25:105-110.
Koski J.M. (1992) Ultrasonographic evidence of synovitis in axial joints in patients with polymyalgia rheumatica. Br J Rheumatol 31:201-203.
Gabay C., Kushner I. (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:448-454.
Suzuki D., Miyazaki M., Jinde K., Koji T., Yagame M., Endoh M. (1997) In situ hybridization studies of matrix metalloproteinase-3, tissue inhibitor of metalloproteinase-1 and type IV collagen in diabetic nephropathy. Kidney Int 52:111-119.
Malide D., Russo P., Bendayan M. (1995) Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients. Hum Pathol 26:558-564.
Hanemaaijer R., Koolwijk P., Clercq L., Vree W.J.A., Hinsberg V.W.M. (1993) Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumor necrosis factor-alpha, interleukin-1 and phorbol ester. Biochem J 296:803-809.
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
